Other
Non-Hodgkin Lymphoma by Clinical Course
CI-CAN-00003432Explore in graph →
Hematologic346 active trials12 approved drugs7 evidence items
- NCIt
- C7215
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00003432Explore in graph →
Clinical trials
1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (209)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | unknown | Phase 2 | 122 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2021 |
| NCT04480788 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | unknown | Phase 1 | 9 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04626739 | CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | unknown | Early Phase 1 | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04620655 | RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL | unknown | N/A | 24 | Min XiangOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT02544425 | VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)(VIDL+ASCT) | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04004637 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04490590 | A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma | unknown | Phase 4 | 30 | Mingzhi ZhangOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04279379 | Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT04337593 | Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 7, 2020 | clinicaltrials |
| NCT04096690 | Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma | unknown | Phase 2 | 22 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT04008394 | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04038411 | PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 4 | 50 | Mingzhi ZhangOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03999697 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03776279 | A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma | unknown | Phase 2 | 106 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT02542124 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | unknown | Phase 2 | 10 | Neumedicines Inc.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03679455 | A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1(OBI-1) | unknown | Phase 2 | 30 | Polish Myeloma ConsortiumOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03701022 | PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 2 | 61 | Peking UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03558412 | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma | unknown | Phase 4 | 40 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03598959 | Tofacitinib Combined With Chidamide in R/R ENKTCL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT01719835 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study(CHEMO-T) | unknown | Phase 2 | 87 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02560441 | Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | unknown | Phase 2 | — | Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01746992 | CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma | unknown | Phase 4 | 200 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03154918 | GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma | unknown | Phase 2 | 60 | Sichuan UniversityOTHER | 1 | Nov 8, 2017 | clinicaltrials |
| NCT03335098 | Study of VTD in Waldenstrom's Macroglobulinemia(BOMB-THROW) | unknown | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT03298828 | CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 | 30 | Third Military Medical UniversityOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT03273452 | Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)(PET) | unknown | Phase 2 | 30 | Qingdao UniversityOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT03267407 | Vietnam Cryptococcal Retention in Care Study - Version 2.1 | unknown | — | 1,184 | National Hospital for Tropical Diseases, Hanoi, VietnamOTHER_GOV | 1 | Sep 12, 2017 | clinicaltrials |
| NCT03265158 | Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0(BMPB) | unknown | — | 108 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT03261349 | Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | unknown | Phase 2 | 21 | National Taiwan University HospitalOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT03107962 | Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma | unknown | Phase 2 | 20 | Mingzhi ZhangOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT03051542 | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT03051555 | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT02987127 | Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma | unknown | — | 21 | National Taiwan University HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02927717 | An Italian Experience on Grade 3b Follicular Lymphoma(FL3b-Oss-2015) | unknown | — | 60 | A.O.U. Città della Salute e della ScienzaOTHER | 0 | Oct 7, 2016 | clinicaltrials |
| NCT02881749 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | unknown | Phase 2 | 68 | Thomas Jefferson UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02878278 | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | unknown | Phase 2 | 24 | Huiqiang HuangOTHER | 0 | Aug 25, 2016 | clinicaltrials |
| NCT02080234 | Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01501136 | Treatment of Natural Killer/T Cell Lymphoma-I/II(CTTNKTL-I/II) | unknown | Phase 4 | 200 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01501149 | Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ(CTTNKTL-Ⅲ/Ⅳ) | unknown | Phase 4 | 80 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2021source: clinicaltrials